(Reuters) – Eli Lilly and Co said on Tuesday treatment with a combination of two of its antibodies helped reduce risk of hospitalizations and death due to COVID-19 by 70%, according to results from a late-stage trial.
The results are from over 1,000 participants of the study, which is testing the combination of bamlanivimab and etesevimab.
(Reporting by Manojna Maddipatla in Bengaluru; Editing by Shailesh Kuber)
